Contact Information: Tigecycline (TG) Salvage Therapy for Legionnaires’ disease (LD) in Severely Ill Patients Deepika Slawek, MD, MPH NYU Langone Medical Center 550 First Avenue New York, NY 10016 Deepika Slawek, MD, MPH, Diana Altshuler, PharmD, Yanina Dubrovskaya, PharmD, Eddie Louie, MD Email:
[email protected] # 1222 NYU Langone Medical Center, New York, NY ABSTRACT (REVISED) OBJECTIVE RESULTS § To describe, retrospectively, the use of TG in hospitalized patients with LD with Background: Mortality due to severe LD remains high with 20-25% of patients Table 1 (cont’d). Patient demographics and clinical presentation (n=12) high severity-of-illness scores or a high degree of immunosuppression who are requiring mechanical ventilation. TG, a minocycline derivative, is active against L. Figure 1. LD Treatment Prior to Starting TG unresponsive to standard monotherapy Required ICU admission 9/12 (75) pneumophila in animal and cell models, achieves high concentrations intracellularly 14 Septic shock 5/12 (42) and demonstrated minimal in vitro synergy with levofloxacin (LVX). Clinical data on TG METHODS for LD are limited to two case reports in immunocompromised hosts. We describe our Duration of ICU stay , days median (range) 12 (1-18) days 12 experience with TG as salvage therapy in severely ill patients with LD. Study Design Required mechanical ventilation 5/12 (42) § IRB approved single center retrospective case series (7/2008-2/2016) Methods: Patient demographics, clinical data and treatment details were collected Duration of mechanical